t
| Date | 10 Feb 2023 |
| Time | 14:15:01 |
| Category | Director/PDMR dealings |
| ID | 6209P |
Celadon Pharmaceuticals Plc
("Celadon" or the "Company")
Notification of transactions by persons discharging managerial responsibility
London, 10 February 2023 - Celadon Pharmaceuticals Plc (AIM: CEL), a UK-based pharmaceutical company focused on the research, cultivation, manufacturing and sale of breakthrough cannabis-based medicines, announces that an award of options to acquire the Company's shares for their nominal value of £0.01 was granted to an Executive Director on 9 February 2023 under the Company's Long Term Incentive Plan ("LTIP") as shown below. The Options will vest on the third anniversary of grant on 9 February 2026, subject to the achievement of performance criteria. Once vested, the awards must be held for two years.
|
1 |
Details of the person discharging managerial responsibilities / person closely associated |
|||||
|
a) |
Name |
Jonathan Turner |
||||
|
2 |
Reason for the notification |
|||||
|
a) |
Position / status |
PDMR - Chief Financial Officer |
||||
|
b) |
Initial notification / Amendment |
Initial Notification |
||||
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||
|
a) |
Name |
Celadon Pharmaceuticals plc |
||||
|
b) |
LEI |
213800YXCATORT475807 |
||||
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||
|
a) |
Description of the financial instrument, type of instrument Identification code |
Ordinary shares of £0.01 GB00BDQYGP38 |
||||
|
b) |
Nature of the transaction |
Award over nominal cost options under the Celadon Pharmaceuticals plc Long Term Incentive Plan |
||||
|
c) |
Price(s) and volume(s) |
|
||||
|
d) |
Aggregated information - Aggregated volume - Price |
N/A Single Transaction |
||||
|
e) |
Date of the transaction |
9 February 2023 |
||||
|
f) |
Place of the transaction |
London |
||||
Enquiries:
|
Celadon Pharmaceuticals Plc |
|
|
James Short Jonathan Turner Arthur Wakeley |
Via Powerscourt |
|
|
|
|
Canaccord Genuity Limited (Nominated Adviser and Broker) |
|
|
Bobbie Hilliam / Andrew Potts / Patrick Dolaghan |
+44 (0)20 7523 8000 |
|
|
|
|
Powerscourt Group |
|
|
Sarah MacLeod / Nick Johnson / Sam Austrums / Ibrahim Khalil |
+44 (0)20 7250 1446
|
About Celadon Pharmaceuticals Plc
Celadon Pharmaceuticals Plc is a UK based pharmaceutical company focused on the research, cultivation, manufacturing, and sale of breakthrough cannabis-based medicines. Its primary focus is on improving quality of life for chronic pain sufferers, as well as exploring the potential of cannabis-based medicines for other conditions such as autism. Its 100,000 sq. ft UK facility operates to an EU-GMP standard and comprises indoor hydroponic cultivation, proprietary GMP extraction and manufacturing and an analytical and R&D laboratory. The Company's subsidiary, LVL, owns a MHRA conditionally-approved clinical trial using cannabis based medicinal products to treat chronic pain in the UK. Celadon also has a minority interest in early-stage biopharma Kingdom Therapeutics which is developing a licenced cannabinoid medicine to treat children with Autism Spectrum Disorder.
For further information please visit our website www.celadonpharma.com